New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

More documents

Recommendations

Info

2 nd Annual Essentials in Primary Care Fall Conference Friday, November 11, 2011 Pitavastatin - Livalo • Mean Change from Baseline to Week 12 Treatment LDL-C Apo B TC TG HDL-C Pitavastatin 2 mg (n= 307) -39% -30% -28% -16% 6% Pitavastatin 4 mg (n= 319) -44% -35% -32% -17% 6% Simvastatin 20 mg (n= 107) -35% -27% -25% -16% 6% Simvastatin 40 mg (n= 110) -43% -34% -31% -16% 7% The most frequent adverse effects, occurring in at least 2% of patients receiving one of the available doses, were myalgia, back pain, diarrhea, constipation, and pain in extremity. Pitavastatin - Livalo • DRUG INTERACTIONS: Several agents (cyclosporine-avoid, rifampin-max 2mg, eryrthromycin-max 1 mg, gemfibrozil and lopinovir/retonavir-caution) have the potential to interact with the organic anion transporting polypeptide–mediated uptake of pitavastatin. • 1, 2, and 4 mg tablets supplied in bottles of 90 tablets. The cost for all three doses is $119.00/30 AWP. Wayne Weart New Drug Update Part I
2 nd Annual Essentials in Primary Care Fall Conference Friday, November 11, 2011 Denosumab – Prolia by Amgen Dosage 60 mg Sub Q every 6 months $990.00/dose AWP Denosumab - Prolia • A fully human monoclonal antibody to the receptor activator of nuclear factor-kappa B ligand (RANKL) . • Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone. FDA approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy Wayne Weart New Drug Update Part I
Page 1 and 2:
2 nd Annual Essentials in Primary C
Page 3 and 4: 2 nd Annual Essentials in Primary C
Page 53: 2 nd Annual Essentials in Primary C
Page 77: 2 nd Annual Essentials in Primary C
show all

New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

Create successful ePaper yourself

Delete template?

Save as template?